Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTH(1-31)
- Development stage
- Phase 2
- Lead developer
- Unigene Laboratories
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Oral, Subcutaneous
01
Overview
**PTH(1-31)** is a recombinant analog of the first 31 amino acids of human parathyroid hormone (PTH), designed as an oral tablet formulation for potential use in osteoporosis treatment. It acts as an intermittent PTH receptor agonist, preferentially stimulating osteoblast activity to promote bone formation over resorption, mimicking the anabolic effects of teriparatide (PTH 1-34). Developed as an oral alternative to subcutaneous PTH analogs, it was investigated in phase 1/2 clinical trials for postmenopausal osteoporosis, showing systemic absorption and increases in bone formation markers like P1NP comparable to Forsteo (teriparatide).[2]
- Other names
- PTH analog
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on PTH(1-31).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTH(1-31).